MedTrace Logo

Evaluation of a Probiotic on LDL-cholesterol Levels

NCT04029818 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-11-15

No results posted yet for this study

Summary

The aim of the present study is to evaluate the ability of Bifidobacterium BSL\_PS404 in reducing LDL-cholesterol levels in healthy individuals.

Conditions

Interventions

BIOLOGICAL

Bifidobacterium BSL_PS404

Each participant will consume 1 capsule daily at lunch for 8 weeks.

BIOLOGICAL

Placebo

Each participant will consume 1 capsule daily at lunch for 8 weeks.

Sponsors & Collaborators

  • Biosearch S.A.

    lead INDUSTRY

Principal Investigators

  • Miguel Quesada, MD, PhD · Medical specialist in Endocrinology, Hospital San Cecilio de Granada

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-24
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04029818 on ClinicalTrials.gov